Imugene Receives $4.13 million R&D Tax Incentive
Filed with ASX · · 2 pages · English
In the deck
Story so far
Earlier from Imugene
- US Defense Grant to Study Imugene CF33 Oncolytic Virotherapy
- CF33 Oncolytic Virus Clinical Trial Program Update
- Comprehensive Phase Ib HER-Vaxx Results Presented at ESMO
- Investor Presentation - Proposed Acquisition
- New HER-Vaxx Cancer Vaccine trial data presented at ESMO GI
Later from Imugene
- Imugene Share Placement to raise $24.6 million
- Imugene HER-Vaxx Immunotherapy Patent Granted in US
- Imugene PD1-Vaxx Immunotherapy Update
- Imugene HER-Vaxx Phase 2 Clinical Update
- Imugene Receives Ethics Approval to Start PD1-VAXX Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene